Abstract
Purchase PDF (260 K)
E-mail Article
Add to my Quick Links
Cited By in Scopus (10)
Purchase PDF (201 K)
doi:10.1016/j.jchromb.2005.01.022 
Copyright © 2005 Elsevier B.V. All rights reserved.
Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques
Emilia Caputoa, b, 1, 
, 
, Maria Luisa Lombardic, 1, Vincenza Luongoc, Ramy Moharramb, Pete Tornatored, 
, Giuseppe Pirozzic, John Guardiolaa, and Brian M. Martinb
Received 2 July 2004;
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
The plasma peptide component (PPC) from ten melanoma (Mel), breast cancer (BC) and healthy individuals was examined by a combination of RP-HPLC, surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) and tandem mass spectrometry. A three peak pattern (2023, 2039, 2053.5 m/z) was primarily observed in melanoma. Two peaks (2236.1 and of 2356.3 m/z) were found only in BC samples. Fibrinogen alpha and inter-α-trypsin inhibitor heavy chain H4 fragments were absent in both tumor samples.
Keywords: Melanoma; Breast cancer; Plasma peptide component; SELDI-TOF MS
Abbreviations: SELDI-TOF MS, surface enhanced laser desorption/ionization time-of-flight mass spectrometry; CHCA, α-cyano-4-hydroxy-cinnamic acid; ACTH, adrenocorticotropic hormone; RT, retention time; CNC, composite normal control; PPC, plasma peptide component
Article Outline
- 1. Introduction
- 2. Materials and methods
- 2.1. Materials
- 2.2. Plasma samples
- 2.3. SELDI-TOF MS analysis
- 2.4. Reverse phase HPLC
- 2.5. SELDI/Qq-TOF tandem mass spectrometry
- 3. Results
- 3.1. RP-HPLC and SELDI-TOF MS plasma peptide profiles in melanoma patients and healthy donors
- 3.2. Plasma peptide composition in breast cancer patients
- 3.3. PPC in individual melanoma and healthy plasma
- 3.4. Peptide sequencing from melanoma and healthy donor plasma
- 4. Discussion
- Acknowledgements
- References
